Administered before tumor engraftment, the vaccine prevents tumor growth by 84% compared to the control, while post-engraftment administration results in a 60% reduction in tumor growth [51].Van Lint et al. formulated a TriMix mRNA adjuvant vaccine that encodes CD70, CD40 ligand, and a constitutively active Toll-like receptor 4. The gene discussed is CD40LG; the disease is neoplasm.